Breaking News
WEBINAR | Haemoglobin Disorders and EU Health Policies, 21 September 2023
IN THE SPOTLIGHT | Explore Our Latest Work in the TIF Newsletter, August Edition
CLINICAL NEWS | FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS
TIF European Health Policy Webinar Series | 21 September 2023
PUBLICATIONS | Nutrition Guide for Patients with Thalassemia & PKD
TIF2023 | 16th International Conference on Thalassaemia & Haemoglobinopathies, November 3-5
DRUGS | EU Pulls Authorization of Adakveo for Sickle Cell Disease
COLD AGGLUTININ DISEASE | Enjaymo Improved Life Quality in Patients for 2.5 Years
NEW SURVEY | Thalassaemia Care Delivery From A Patient Perspective
NEWS | WHO Updates Essential Medicines List, Adds New Medicines for Thalassaemia
English
English
Ελληνικά
Français
Deutsch
Italiano
العربية
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country Work
Projects
Global Thalassaemia Review
COVID-19 Pandemic & TIF
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Home
/
What we do
What we do
Back to top button
Close
Search for
